Two medicines, side by side
Nifedipine vs metoprolol
Nifedipine and metoprolol are both labeled for high blood pressure and angina. Drugs@FDA records approvals of nifedipine since 1981 and of metoprolol since 1978. Pharmacies paid $0.130 per nifedipine ER 30 mg tablet and $0.085 per metoprolol succ ER 100 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. Metoprolol's other strengths are brand-only: $1.20 per mL (Lopressor 10 mg/mL oral solution). In FDA's classes, nifedipine is a dihydropyridine calcium channel blocker and metoprolol a beta-adrenergic blocker.
Check it at the source: the nifedipine FDA label on DailyMed (effective December 24, 2024); the metoprolol FDA label on DailyMed (effective March 3, 2026).
Highlights of the nifedipine record
Nifedipine (Procardia) · label of December 24, 2024
Used for
From the label: indicationsNifedipine extended-release tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
On the market
- Earliest approval on file
- December 31, 1981
- Generic labelers
- 32 labelers
- Pharmacy cost
- $0.130 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 7
Highlights of the metoprolol record
Metoprolol (Lopressor) · label of March 3, 2026
Used for
From the label: indicationsTOPROL-XL, metoprolol succinate, is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. […]
On the market
- Earliest approval on file
- August 7, 1978
- Generic labelers
- 74 labelers
- Pharmacy cost
- $0.085 per tablet
Supply and safety
- Shortage
- A presentation being discontinued
- Recalls
- 39
Source: FDA drug labels via openFDA (Nifedipine label of December 24, 2024, Metoprolol label of March 3, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do nifedipine and metoprolol differ on the record?
In FDA's classes, nifedipine is a dihydropyridine calcium channel blocker and metoprolol a beta-adrenergic blocker.
Half-life, in each label's words: Nifedipine, “The elimination half-life of nifedipine administered as nifedipine extended-release tablets are approximately 7 hours …”; Metoprolol, “Elimination Elimination is mainly by biotransformation in the liver, and the plasma half-life ranges from approximately …”
Generics: nifedipine since 1989; metoprolol since 1993 (Drugs@FDA).
| Nifedipine | Metoprolol | |
|---|---|---|
| Labeled for | High blood pressure, Angina | High blood pressure, Angina, Heart failure, Heart attack and coronary artery disease |
| Pharmacologic class | Dihydropyridine Calcium Channel Blocker | beta-Adrenergic Blocker |
| How it works (label) | n/a | Metoprolol is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent. |
| Half-life (label) | The elimination half-life of nifedipine administered as nifedipine extended-release tablets are approximately 7 hours in contrast to the known 2 hour elimination half-life of nifedipine administered as an immediate … | Elimination Elimination is mainly by biotransformation in the liver, and the plasma half-life ranges from approximately 3 to 7 hours. |
| Earliest approval on file (Drugs@FDA) | December 31, 1981 | August 7, 1978 |
| First generic approved | April 28, 1989 | December 21, 1993 |
| Generic labelers (NDC) | 32 labelers | 74 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.130 per tablet (Nifedipine ER 30 mg tablet) | $0.085 per tablet (Metoprolol succ ER 100 mg tablet) |
| 12-month price change | +19% | -8% |
| Boxed warning | No | No |
| Shortage now | No current entry | A presentation being discontinued |
| Recalls recorded | 7 | 39 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 41,059 | 353,609 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to nifedipine
- every medicine labeled for the same conditions